Merit Medical Systems, Inc. acquired View Point Medical, Inc. through a merger transaction, making View Point a wholly-owned subsidiary. The acquisition includes View Point's OneMark Detection Imaging System, OneMark Tissue Markers, and related assets. The total acquisition consideration is approximately $140 million, including assumed liabilities. $90 million was paid in cash at closing on April 1, 2026. Two deferred payments of $25 million each are scheduled for the first and second anniversaries of the closing date. The OneMark System is US FDA cleared and offers ultrasound-enhanced technology for localizing breast and soft tissue tumors at the time of biopsy. The acquisition is projected to contribute $2 million to $4 million in revenue for the remainder of 2026 and to be dilutive to non-GAAP EPS by approximately $0.05 for the same period. For the full year 2027, the acquisition is projected to contribute $14 million to $16 million in revenue and to be accretive to non-GAAP EPS. Sales of the OneMark System are projected to grow at least 20% per year with 70% non-GAAP gross margins.